https://www.selleckchem.com/pr....oducts/sivelestat-so
24). The median overall survival (OS) was 14.2 and 11.5months in the S-IROX and mFFX groups (p = 0.34). There were no significant differences in the incidences of grade 3-4 adverse effects. The subgroup analyses suggested S-IROX demonstrated favorable OS in patients with PFS ≥6months of first-line gemcitabine plus nab-paclitaxel (p for interaction = 0.02). S-IROX and mFFX were similarly tolerable and effective as a second-line chemotherapy in patients with PC refractory to gemcitabine plus nab-paclitaxel. S-IROX and mFFX were
Like
Comment
Share
